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Abstract
Improving health through better nutrition of the population may contribute to enhanced efficiency and sustainability of healthcare systems.
A recent expert meeting investigated in detail a number of methodological aspects related to the discipline of nutrition economics. The role
of nutrition in health maintenance and in the prevention of non-communicable diseases is now generally recognised. However, the main
scope of those seeking to contain healthcare expenditures tends to focus on the management of existing chronic diseases. Identifying
additional relevant dimensions to measure and the context of use will become increasingly important in selecting and developing outcome
measurements for nutrition interventions. The translation of nutrition-related research data into public health guidance raises the challen-
ging issue of carrying out more pragmatic trials in many areas where these would generate the most useful evidence for health policy
decision-making. Nutrition exemplifies all the types of interventions and policy which need evaluating across the health field. There is
a need to start actively engaging key stakeholders in order to collect data and to widen health technology assessment approaches for
achieving a policy shift from evidence-based medicine to evidence-based decision-making in the field of nutrition.
Key words: Nutrition economics: Health technology assessment: Preventive interventions: Cost-effectiveness: Public health
guidance
Escalating healthcare costs have become a major concern
for decision-makers, prompting development of innovative
cost containment measures(1,2). In Europe, health authorities
have started to establish incentives for efficient healthcare
delivery by means of decentralisation of the healthcare
decision-making process and implementation of market
mechanisms(3). Cost-effectiveness analysis has become
common practice for informing reimbursement decisions for
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pharmaceuticals and other health technologies including
devices(4). Nutrition interventions tend to be excluded from
these processes, although healthcare decision-makers have
begun to realise that food plays an important role, not only
in those already with disease, but also in the onset and evol-
ution of lifestyle-related disorders. Indeed, improving health
through better population nutrition may contribute to the
cost-effectiveness and sustainability of healthcare systems. It
is therefore essential to describe and quantify the costs and
effectiveness of nutrition interventions, both the immediate
costs of the intervention and downstream consequences,
and to assess impacts for individuals, the healthcare system
and society as a whole. The discipline of nutrition economics,
currently being established, is relevant and timely for inform-
ing decision-making. First, this discipline helps to better
inform health authorities and consumers on the harms of
poor nutrition and on the benefits of making certain food
choices. Second, the discipline is essential to governments in
designing efficient public population-scaled interventions
and educational campaigns. A third focus is on nutrition inter-
ventions delaying disease onset or progression. Finally, nutri-
tion economics is also relevant for improving the nutritional
quality of foods produced by industry.
To identify and explore the field of nutrition economics, a
first expert meeting was held in February 2010. This exchange
resulted in a consensus about the importance of defining this
new area and led to the establishment of a first multidisciplin-
ary approach to understanding the principles, relevance and
particular characteristics of the field of nutrition economics(5).
A second meeting was held in Madrid, in October 2011 with
the goal to investigate in detail a number of methodological
concepts and issues. Nutrition interventions vary from specific
individual treatments to broad public health measures, and
therefore their evaluation requires a range of different
approaches. They depend on involvement of the target audi-
ence in the decision to engage in the ‘intervention’, often with-
out the support provided in adhering to a specific treatment
on medical prescription. The feasibility of expressing the
multidimensional impact of nutrition on the individual’s qual-
ity of life in a single outcome measure has yet to be fully
addressed. The need to enhance capacity in the evaluation
of complex multi-component interventions formed the focus
of the panel discussions reported below.
Health economics and nutrition
Cost-effectiveness analyses aim to provide reliable, reproduci-
ble and verifiable insight into the effectiveness of an interven-
tion, the costs of its implementation and the potential
downstream savings. Cost-effectiveness analyses in nutrition
interventions tend to rely heavily on health economic model-
ling, as a long-term follow-up is required to appropriately
measure impacts, which invariably extend far beyond the
periods of intervention. The challenges of a long-term
follow-up are many, including handling of dropouts, study
investment costs and changes in technology or society,
which can render the original intervention or control context
unrealistic. Nutrition interventions are often preventive; they
can be implemented at the population level or individually
and employ various methods including health promotion,
social marketing, consumer research, clinical consultation
and financial incentives such as taxes, subsidies or regulations.
Nutrition interventions cover the cycle from farm to fork and
thus extend well beyond the health sector. Nutrition econ-
omics and the economic evaluation of nutrition interventions
must therefore deal with a wide range of issues.
Nutrition and health-related quality of life assessment
The concept of health-related quality of life (HRQL) is relevant
to health-economic evaluations wherever quality of life
impacts are expected, which will typically be the case with
nutrition interventions. HRQL is a multidimensional concept
and encompasses several aspects including (1) the person’s
functional status across various domains, such as physical,
occupational and interpersonal, and (2) the person’s appraisal
of how his/her health affects his enjoyment or quality of life(6).
One proposed definition of HRQL is: ‘the subjective percep-
tion of the impact of health status, including disease and treat-
ment, on physical, psychological, and social functioning and
wellbeing’(7). However, this does not mean that it is a subjec-
tive measure. Indeed, a measurement instrument that is vali-
dated according to rigorous validity criteria can objectively
assess subjective phenomena(8). In contrast to traditional end-
points used in clinical trials, the responses to quality-of-life
questionnaires directly reflect the subject’s own perspective
on his/her health status. The scope of HRQL measures is not
limited to patients with defined symptomatic diseases, but
can also be used in a general population setting. These
measurements are valuable in providing preference-based
‘utility values’ used in economic evaluation studies. Several
concepts(9,10), techniques(11,12) and instruments(13,14) are avail-
able for assigning a utility value to a particular health state.
Validated non-preference-based HRQL measures provide
additional information on the subject’s own viewpoint on
health conditions and their management.
The principles of health economic evaluation apply to all
health technologies. Thus, it makes sense to establish whether
the existing methods provide reliable information on nutrition
interventions, before addressing methodological problems
specifically related to the field of nutrition. The different
health outcome measures have in common that they ascribe
the same weight regardless of who gains the benefit. Equity
weighing is possible and has been used(15), but this does
not imply that fairness and equity in health is taken into
account automatically(16). Also, characteristics such as person-
ality, cognitive dysfunction and psychological adaptation to
illness may influence how a person responds to the
items(17,18). Notwithstanding the imperfections, these
measures are very practical for decision-makers.
Other issues related to nutrition have remained largely
unexplored until today. A nutrition intervention may operate
very differently from drug treatment, and this needs to be
addressed. Some existing paradigms require adjustment in
order to include dimensions that are not captured using tra-
ditional measures. Food can serve in a context of prevention,
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treatment, palliative care, etc., and this will inform the devel-
opment of an appropriate endpoint model and condition the
items to be measured.
A few more general considerations were discussed, in par-
ticular the need to consider the individual’s satisfaction. It is
important to have this dimension captured in the matrix for
quality of life assessment in nutrition. A recent Food and
Drug Administration Public workshop on Clinical Trial Out-
come Assessments emphasised the need to define the context
of use for validating outcome assessments: interestingly, the
impact on general life concepts presented included pro-
ductivity, health status, HRQL as well as satisfaction with
health(19). In addition, many subjects who are not diseased
but have a known risk factor, e.g. a high LDL-cholesterol con-
centration or a low bone mineral density, will prefer not to
take drugs to avoid being labelled as a patient or through
fear of drug-related adverse effects(20). The choice not to
pursue medication is a component that is often not captured
when assessing quality of life, partly because that target popu-
lation is unlikely to enter a trial. Assessing the HRQL impact of
prevention in a sub-healthy individual is extremely relevant in
nutrition, since the awareness of being at risk for developing a
disease might also affect quality of life(21).
In summary, for comprehensive outcome measures for
nutrition in a daily setting, the appropriate assessment tools
have to be selected based on the context and the research
question.
Health technology assessment and decision-making
Health technology assessment (HTA) provides evidence and
analysis for different levels of decision-making: micro –
clinicians, meso – managers; and macro – policy makers.
HTA seeks to provide health authorities and professionals
with accessible and usable information to guide their
decisions, whether these are used for advice on individual
technologies or intended as guidelines for the management
of health concerns and target populations. The scope of
HTA needs to incorporate broad-ranging issues, including
social values, legal concerns, ethical aspects and organis-
ational issues, as well as clinical benefits and cost-effective-
ness. The focus of a particular HTA will depend on the
decision context – who needs the information and for what
type of decision. Properly used, HTA helps to produce trans-
parent, accountable and evidence-based decisions. However,
HTA has been mainly associated with drug and medical
device reimbursement decisions, where, in many countries,
financial considerations of affordability may be as important
as clinical and cost-effectiveness. Although a decision-
making process in the field of nutrition economics will in gen-
eral not involve reimbursement for individual products, inter-
ventions to change public awareness of, and attitudes to,
nutrition will have a cost, which needs to be justified against
other uses of health budgets. For example, in the case of
initiatives to change eating patterns by introducing taxes on
unhealthy or unbalanced food products, the consequences
in terms of economic efficiency and social equity need to be
carefully evaluated during the decision-making process.
Although the intention is to improve public health, the econ-
omic consequences of such taxation could induce an opposite
effect or lead to increasing health inequalities(22,23).
Another important consideration is the impact of policies
which are primarily designed to meet non-health objectives,
but which have a major effect on health. In the field of nutri-
tion, there are clear links with agricultural policies. Reports
from the European Commission indicate that the health
impact of policies is often secondary to economic or regional
policy interests(24) and support the idea that health is not
necessarily considered in an appropriate manner in impact
assessments(25).
These factors offer an interesting opportunity for the appli-
cation of the HTA evaluation framework in the field of nutri-
tion economics, where equity and efficiency considerations
may be equally important. The general population and
decision-makers are not only interested in efficiency but also
in equity in the distribution of health(26). Current initiatives
to apply comprehensive economic evaluation methods to
public health interventions, including those in nutrition,
should be continued(27).
The use of models in the nutrition arena
The use of models in economic evaluation combines different
types of data sources to extend available information. Models
can be used to simulate costs of trial modalities, to generalise
trial results, to translate evidence from randomised clinical
trials (RCT) into daily practice or to explore the potential
value of additional evidence from empirical research. Several
types of models can be used in the area of nutrition. One of
them is the decision tree, comparing two or more health strat-
egies. It defines intervention pathways and then links costs
and outcomes to all the possible options. Another type of
model is the Markov model, organised around health states
rather than around pathways(28). In this case, the data input
will be based on probabilities of transitions between succes-
sive health states and specific costs and utilities associated
with the various health states(29). Still other modelling tech-
niques that can be used in nutrition economics are methods
that stem from epidemiology, such as the population attribu-
tive fraction and the potential impact fraction(30). Modelling
techniques usually extrapolate the available short-term evi-
dence over time in order to estimate outcomes beyond the
study period or to link intermediate endpoints to final out-
comes. This approach represents a valuable contribution in
decision-making processes that face the challenging task of
achieving small but tangible modifications of dietary beha-
viour in order to reduce nutrition-related chronic health con-
cerns on the long term(31). The need for a long-term follow-
up, in the general or in a healthy at-risk population, may be
solved by extrapolation methods; these are not specifically
related to nutrition, but more to underlying available evidence
and relationships. A good illustration can be found in the
North Karelia Project. In this Finish province, a major
preventive project was launched in the early 1970 s with the
aim to reduce the high morbidity and mortality associated
with CVD. The programme was a result of a petition by
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representatives of the people, who were concerned about the
data from national statistics(32). The intervention, originally set
up for a period of 5 years, became national and led in the late
1980s to an intensified action, when surveys showed that the
reduction of blood cholesterol was levelling off. The dietary
changes in Finland resulting from the intervention, i.e.
changes in food supply and nutritional and lifestyle rec-
ommendations, have led to an 80 % reduction in annual
CVD mortality rates among the working-age population, and
a major increase in life expectancy has been observed, as
well as improvements in functional capacity and health(33,34).
Lifestyle study programmes(35), cross-sectional surveys(36)
and cohort studies(37,38) allow us to develop risk equations
for disease progression that include the quality of the diet.
The Australian longitudinal study on Women’s Health illus-
trates the opportunity to explore dietary patterns and the
relationship between diet and diverse health outcomes,
including healthcare costs(39). The foregoing discussion under-
lines that evidence requirements have to be fulfilled in two
complementary ways: by clinical evidence from RCT and by
epidemiological observations and national statistics.
The quality of evidence
Healthcare guidance must be based on best available
evidence(40,41). It is not limited to the clinical situation; often
the guidance is intended to other public agencies in the edu-
cation and social service sectors or directly to individuals. In
the case of therapeutic interventions, the properly conducted
RCT is commonly recognised as the gold standard for clinical
efficacy. This criterion relates to the issue of preferring internal
validity to external validity(42). The difficulty of using a RCT is
its translation to the population level and linking results of
clinical intervention trials with high internal validity in terms
of treatment outcomes in routine practice(43). This translation
is especially challenging in nutrition because of more con-
founding variables and the greater difficulty in controlling
nutritional factors when compared with pharmaceutical
treatments.
As previously mentioned(5), the lifestyle setting and a need
for high external validity justify the use of other types of evi-
dence, such as cohort studies and other observational data.
Clinical trial populations do not match the population likely
to be treated with the study intervention. New methods and
new developments have been produced, not as much related
to the clinical effect, but more to the clinical relevance and
final results on a totality of subjects(44). It will be of great inter-
est to translate this approach to the field of nutrition econ-
omics, where the final endpoint is the relevance for society.
The issue is not restricted to defining the level of evidence
but also includes translation of the evidence into public
health guidance in terms of nutrition interventions, which
raises the challenging issue of generalisability to daily practice.
To move into the territory of another type of best evidence,
a gradual strategy could be considered in order to obtain
robust data. Such a strategy begins at the most serious end
of a nutrition-related chronic health concern and then is
gradually taken upwards. If an effect is observed, the cost of
doing so remains limited and when moving further and further
up the intervention pathway, the population becomes larger.
The research question needs of course to be correctly defined
before starting the study and although individual effects might
get smaller, the global impact on public health and healthcare
expenditures is more likely to attain significance. The process
of producing guidance based on the best available evidence is
crucial to allow robust and accountable decision-making pro-
cesses(45). Nutrition should be no exception to this rule.
In recent years, the Grading of Recommendations Assess-
ment, Development and Evaluation approach has been used
as a system for rating quality of evidence and strength of rec-
ommendations. It is claimed to be explicit, comprehensive,
transparent and pragmatic, and is increasingly being adopted
by organisations worldwide(43). The approach is mostly
devoted to recommendations for clinical practice and has
been applied to recommendations on individuals or health
technologies(47). However, this approach should also be
tested in terms of its usefulness for public health interventions
and modified accordingly if found to be insufficient.
The importance of evidence-based guidance for nutrition
Clinical guidelines include the role of nutrition in the manage-
ment of some metabolic diseases, for instance diabetes(48), but
do not routinely do so for other diseases where nutrition can
be important. The incorporation of a new intervention
modality into clinical guidelines depends on the evidence
for the efficacy and safety of a new intervention. The rec-
ommendation in clinical guidelines is an important criterion
for the choice of prescription modalities by healthcare provi-
ders, and if a new intervention strategy is not included in
the clinical guidelines, healthcare professionals will be hesi-
tant to apply it. If the guidelines advised consideration of
diet and exercise before any drug prescription(49,50), health-
care costs might be reduced (Fig. 1). In producing guidance,
cost-effectiveness must also be considered. Escalating costs
have resulted in a demand for cost-effectiveness data in the
decision-making process. Therefore, interventions should be
assessed on their cost-effectiveness v. standard practice
before being included in guidelines(51). Some countries have
defined a cost-effectiveness threshold in terms of maximum
cost per quality adjusted life year (QALY), which interventions
must meet before being considered cost-effective and there-
fore reimbursable. The UK is the only European country to
be explicit about the cost-effectiveness threshold it uses. The
WHO has proposed thresholds on an arbitrary basis (http://
www.who.int/choice/costs/CER_thresholds/en/index.html) and
countries may seek to depart from these for various reasons.
Countries may also seek to adopt a more complex approach
that takes account of other factors such as the type of interven-
tion, the target population, and the quality and certainty of
evidence. In reality, in most countries, the health authorities
seem to prefer to make decisions without defining clear
thresholds or communicate them to the public domain, allow-
ing considerable discretion for policy makers. It is still unclear
what would constitute an appropriate cost-effectiveness thre-
shold to apply in a lifestyle-oriented setting.
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Discussion – the future agenda
Nutrition is an aspect of lifestyle and is subject to individual
choice. Should society take it into consideration and more
actively promote nutrition interventions that improve overall
public health and thereby reduce healthcare costs? Should
nutrition economics therefore be linked more closely to
social values and would these be more relevant than in
other fields of health economics? Identifying the concepts to
measure and the context of use will be a key consideration
in selecting and developing HRQL measurements for nutrition
interventions. Satisfaction was frequently mentioned during
the meeting and opposing views about the interest of includ-
ing it in assessments were expressed. Some panel members
argued that individual satisfaction is an important driver in
motivating people and can therefore improve the impact of
public health interventions. Others considered that was not
the case, although they conceded that healthy food choices
can be enjoyable and help in achieving changes in behaviour.
At the moment, nutrition is generally not often taken into
account by those seeking to reduce healthcare expenditures.
This does not mean that nutrition should necessarily be
included in the reimbursement system to attract the attention
of decision-makers. By showing the outcomes of some of
the measures and strategies already used(52–55), the nutrition
economic approach is likely to quickly gain interest among
decision-makers. What is more, current strategies to address
the issue of the ageing population and the consequent
increasing demands on healthcare systems from the manage-
ment of chronic diseases should recognise the value of inter-
ventions on lifestyle including nutrition. These interventions
provide opportunities for societal organisations, healthcare
providers and food businesses to develop new technologies
and products while using nutrition economic assessments to
support their strategies.
At present, a major issue is to build up expertise within the
clinical community to run trials in nutrition-related matters to
obtain evidence that can support decisions on interventions
and that provide good value for money. Most investigators
are used to a very restrictive phase III-type RCT, but policy
evaluations are of a different nature. So far, we have fallen
short of carrying out more pragmatic trials in many areas
where these would generate the most useful data. The hard
work that was done in the evaluation of medical technologies,
set up conceptually from the late 1960s onwards and devel-
oped simultaneously in different places, in the absence of
electronic communication, resulted only 30 years later in the
creation of dedicated structures, organisations and networks,
e.g. IQWIG (Institut fu¨r Qualita¨t und Wirtschaftlichkeit im
Gesundheidswesen), HAS (Haute Autorite´ de Sante´), NICE
(National Institute for Health and Clinical Excellence),
INAHTA (International Network of Agencies for Health Tech-
nology Assessment), EuroScan, EUnetHTA (European Net-
work for Health Technology Assessment), and so on. This
was the time needed to build up sufficient examples of its
application and to show that the methodology actually is a
valuable aid in health policy decision-making. The field of
nutrition economics is now in a comparable situation of ‘infor-
mation gap period’, and there is a need to start actively
engaging key stakeholders to collect data, using measures
that decision-makers will recognise. Within nutrition, some
common metrics can be identified which allow us to judge
the relative merits of clinically led interventions and public
health advice. Then, as nutrition exemplifies all the types of
interventions and policy which need evaluating across the
Overweight
Insulin resistance
Increased LDL-C
Hypertension
Reduced bone mass
Age-related 
undernutrition
Obesity and
type 2 diabetes
Cardiovascular
diseases and stroke
Osteoporosis and
sarcopenia
300 million people*
177 million people*
> 15 million deaths
per year*
8 million fractures
per year†
Diet and
exercise
First-line
treatment
Second-line
treatment
Multiple
prescription
 modalities
Non-compliance
Compliance but
lack of effect
Treatment
failure
Paradoxical
effects
Treatment
failure
Potential cost savings
in healthcare
Fig. 1. Common conditions of ill health in the general population and treatment pathways – extension of nutritional strategies for managing many non-communic-
able diseases would considerably reduce healthcare expenditures. *http://www.who.int; †http://www.iofbonehealth.org (accessed 17 May 2012). LDL-C,
LDL-cholesterol.
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health field, the demonstration that many nutritional issues
have not been dealt with correctly in the current context
will further enable us to enrich the basic outcome data and
to develop more relevant approaches. This may then give
insights into ways in which the overall HTA paradigm can
be widened and thus contribute to broadening out the con-
cept of the social welfare function beyond simple incremental
cost-effectiveness ratios and application of qualitative judge-
ments on equity, as happens in current decision-making.
This may further lead to interactions with policies from
other sectors which have health implications through the
medium of nutrition such as agricultural policy, food pricing
and taxation.
It is time to change the paradigm from the micro-level
of evidence-based medicine to evidence-based decision-
making, including meso- and macro-levels, and to convince
health authorities that there should be a policy shift by intro-
ducing up-to-date knowledge of the importance of nutrition.
The authors welcome any feedback and suggestions for
further substantiating the value of nutrition interventions in
the optimisation of public health.
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